Skip to main content
    C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.59
    -0.24 (-0.83%)

    Market Cap: $2.26B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Celldex Therapeutics Inc (CLDX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Celldex Therapeutics are Xencor (XNCR), Disc Medicine (IRON) and Sellas Life Sciences Group (SLS). By market cap, Celldex Therapeutics ranks 11th of the 13 companies on this page; Disc Medicine (IRON) is the largest at $3.64B.

    Peer Comparison

    CLDX's revenue growth of -97.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Celldex Therapeutics (CLDX)$2.26BN/AN/A0.0%N/A-97.0%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Disc Medicine Inc. (IRON)$3.64BN/AN/A0.0%-40.0%0.0%0.00%
    Sellas Life Sciences Group Inc (SLS)$1.60BN/AN/A0.0%N/A-82.5%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Telix Pharmaceuticals Limited (TLX)$3.14BN/A5.3x3.8%-0.7%22.3%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Celcuity LLC (CELC)$3.15BN/AN/A0.0%-25.2%0.0%0.00%
    Vericel Corp Ord (VCEL)$2.91B89.8x9.1x10.3%N/A26.5%0.00%
    Dyne Therapeutics Inc (DYN)$3.22BN/AN/A0.0%-42.9%0.0%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Denali Therapeutics Inc (DNLI)$3.00BN/A159.3x0.0%N/A-100.0%0.00%
    Replimune Group Inc (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Peer median$2.96B178.2x11.3x0.0%-29.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Celldex Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors
    Disc Medicine Inc. (IRON)
    Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development...
    IRON competitors
    Sellas Life Sciences Group Inc (SLS)
    SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications...
    SLS competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Telix Pharmaceuticals Limited (TLX)
    Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic...
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Celcuity LLC (CELC)
    Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States.
    CELC competitors
    Vericel Corp Ord (VCEL)
    Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures...
    VCEL competitors
    Dyne Therapeutics Inc (DYN)
    Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases...
    DYN competitors
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Denali Therapeutics Inc (DNLI)
    Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
    DNLI competitors
    Replimune Group Inc (REPL)
    Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
    REPL competitors

    Frequently Asked Questions About CLDX

    Who are Celldex Therapeutics' main competitors?

    The companies most similar to Celldex Therapeutics include Xencor (XNCR), Disc Medicine (IRON), Sellas Life Sciences Group (SLS), Legend Biotech (LEGN) and Telix Pharmaceuticals (TLX), listed from the closest match.

    Who is Celldex Therapeutics' biggest competitor?

    Disc Medicine (IRON) is the largest of the similar companies at $3.64B; Xencor (XNCR) is the closest match by business profile, size, sector and industry.

    How does CLDX stock compare with its competitors?

    CLDX's net margin is 0.0% against a peer median of 0.0%.

    Which of Celldex Therapeutics' competitors pays a higher dividend?

    Celldex Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Celldex Therapeutics bigger than its competitors?

    No. Celldex Therapeutics is 11th by market cap among the 13 companies on this page; the largest is Disc Medicine (IRON) at $3.64B.